Side-by-side · Research reference

AdipotidevsFOXO4-DRI

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BAnimal-StrongHUMAN-REVIEWED12/45 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

FOXO4-DRI

Senolytic Peptide · D-Retro-Inverso

p53-TADMolecular targetBourgeois 2025

Pre-clinicalDevelopment stage

SQRoute (animal)

SQ · Animal models only

01Mechanism of Action

Parameter

Adipotide

FOXO4-DRI

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

FOXO4-p53 protein complex in senescent cellsBourgeois 2025 Tripathi 2021

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021 Alameen 2026

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

—

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

FOXO4-DRI

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

5 mg/kg

SQ injection, aged mouse model (testosterone restoration).

Route

Intravenous (systemic injection)

SQ (animal)

No human route established.

Frequency

Not specified in available data

—

Evidence basis

Preclinical animal models only

Animal / mechanistic

Human data

None — no clinical trials reported

—

Frequency (animal)

—

Variable — single or intermittent dosing

Protocol-dependent; no standardised regimen.

Human equivalent (theoretical)

—

~0.4 mg/kg (28 mg / 70 kg adult)

Extrapolated using allometric scaling; no clinical validation.

Duration

—

Weeks to months (animal studies)

Senescent cell clearance observed within weeks.

Clinical status

—

No human trials completed

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

FOXO4-DRI

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

FOXO4-DRI

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

Pulmonary hypertension risk

—

Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023

Context-dependent toxicity

—

Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023

Off-target apoptosis

—

Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)

Immune perturbation

—

Senescent cells contribute to immune surveillance; clearance effects unknown

Human safety unknown

—

No clinical trials — toxicity profile in humans not established

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

FOXO4-DRI

·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
·Pregnancy / lactation (no safety data)

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

FOXO4-DRI

·Active malignancy (senescence as tumour suppressor mechanism)
·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)

05Administration Protocol

Parameter

Adipotide

FOXO4-DRI

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Subcutaneous injection used in rodent models. No human administration protocol exists.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.

5. Safety monitoring (proposed)

—

Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.